Individualizing follow-up for patients with early-stage melanoma.

8:88-93, 2009 10. Sanoff HK, Sargent DJ, Campbell ME, et al: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26:5721-5727, 2008 11. Chau I, Brown G, Cunningham D, et al: Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24:668-674, 2006 12. Nogué M, Salud A, Vicente P, et al: Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: The AVACROSS study. Oncologist 16:614-620, 2011 13. Baxter NN, Habermann EB, Tepper JE, et al: Risk of pelvic fractures in older women following pelvic irradiation. JAMA 294:2587-2593, 2005 14. Kollmorgen CF, Meagher AP, Wolff BG, et al: The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg 220:676-682, 1994 15. Peeters KC, van de Velde CJ, Leer JW, et al: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients—A Dutch Colorectal Cancer Group study. J Clin Oncol 23:6199-6206, 2005 16. Schrag D, Weiser MR, Goodman KA, et al: Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. J Clin Oncol 28:263s, 2010 (suppl; abstr 3511)